PDA

View Full Version : Briefing - Asia Health - Dec 21, 2005



Mee
12-22-2005, 12:01 AM
http://sg.biz.yahoo.com/051221/16/3xewx.html



Briefing - Asia Health - Dec 21, 2005

An executive briefing on Health for Dec 21, 2005, prepared by Asia Pulse (http://www.asiapulse.com) (http://www.asiapulse.com%29), the real-time, Asia-based wire with exclusive news, commercial intelligence and business opportunities. FORMER GM OF FAILED AUSTRALIAN DRUG MAKER PAN IS CHARGED

SYDNEY - Charges have been laid against the former general manager of failed complementary drug maker Pan Pharmaceuticals.

<img style="display: none;" alt="" border="0"> (http://sg.rd.yahoo.com/SIG=12gjjtvbr/M=317344.5487680.6569810.3272417/D=sgfinews/S=36086229:LREC/Y=SG/EXP=1135310006/A=3008992/R=3/id=noscriptclick/*http://asia.education.yahoo.com) John Frederick Brennan, 58, is facing 12 charges, brought by the Therapeutic Goods Administration (TGA), relating to the manufacture and export of counterfeit Pan goods in 2002. INDIA'S NATCO SIGNS LOI WITH AKORN FOR ANT-EMETIC CANCER DRUGS

NEW DELHI - To enter the US and European markets, Natco Pharma (BSE:524816) on Tuesday said it had signed a "letter of intent" with US-based Akorn Inc to develop and supply two abbreviated new drug application (ANDA) oral tablet drugs for cancer patients suffering from nausea and vomiting.

The company said as per the letter of intent the two parties expected executing a definitive agreement within 90 days "upon terms and conditions agreeable" to both Akorn and Natco. JAPAN'S TOSHIBA MEDICAL STRENGTHENING X-RAY IMAGING BIZ IN US

TOKYO - Toshiba Medical Systems Corp. is bolstering its X-ray imaging equipment business in the U.S., introducing a new system there before rolling it out in Japan or Europe.

The new system uses X-rays to capture images of blood vessels inside the body of a patient lying on an attached table. By rotating the direction of X-ray exposure, the system can display the blood vessels in 3-D computer graphics, making it useful in diagnosis and surgery related to cerebral aneurysms and heart attacks. S. KOREAN UNIVERSITY TO DELAY MID-TERM REPORT ON STEM CELL PROBE

SEOUL - South Korea's top university said Wednesday it will delay a mid-term report on ongoing investigations to verify the authenticity of embattled stem cell pioneer Hwang Woo-suk's work.
"The ad-hoc panel had planned to hold a press briefing on Thursday, but decided to it off until after Friday," a spokesperson for Seoul National University (SNU) said. The official said the extra time is needed to conduct a thorough reexamination of Hwang's stem cell work. SCHATTEN ASKED HWANG FOR CONTRIBUTION: PITTSBURGH UNIVERSITY

WASHINGTON - University of Pittsburgh professor Gerald Schatten made a proposal for a US$200,000 contribution to South Korean stem cell pioneer Hwang Woo-suk to build a stem cell hub in the United States, a spokeswoman at the the school said Tuesday.

The "detailed budget for initial budget period" was made in September, said Jane Duffield, the spokeswoman for the university's medical center. She told Yonhap News Agency that nothing came of the proposal and that it must be seen as a discussion document only. PRODUCT PATENT REGIME CHANGED INDIAN PHARMA SECTOR IN 2005

NEW DELHI - India entered the product patents regime from January 2005 with the enactment of the Patents (Amendment) Act of 2005, thus heralding a new era in the country's pharmaceutical sector, which has been pegged to attain a size of US $25 billion by 2010.

The new patent regime raised apprehensions that drug prices might go out of reach of the common man but the government tried to come up with a new pharmaceutical policy as an attempt to allay these fears. INDIA'S DISHMAN PHARMA ACQUIRES SWISS COMPANY

MUMBAI - Ahmedabad-based Dishman Pharmaceuticals & Chemicals Ltd (BSE:532526) has acquired a Switzerland-based contract research company, 'I03S Ltd', through a Swiss subsidiary.

The Swiss company, located in Bern, is the only company in the world in the field of consultancy and research in ozone chemistry, Dishman Pharma on Monday informed the stock exchanges.
(C) Asia Pulse Pte Ltd.
CONTACT:
Asia Pulse Production Centre
Phone: (612) 9322 8634
Fax: (612) 9322 8639
http://www.asiapulse.com
ASIA PULSE

mk99
12-22-2005, 10:47 AM
Thanks for the post Mee. I hope you don't mind but I have moved it to the Health & Science News forum. thanks